Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM2038 in Chronic Low Back Pain
NCT02946073Phase 3Completed
- Sponsor
- Braeburn Pharmaceuticals
- Start
- Sep 2016
- Primary completion
- May 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic low back pain (CLBP) comparing CAM2038 with Placebo (2 arms). Primary endpoints: Weekly Average of Daily Average Pain Intensity at 12 weeks and Weekly Average of Daily Average Pain Intensity Open Label at 48 weeks. Started Sep 2016; status: completed.
02
Drugs
buprenorphine
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT02946073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946073.